Clinical trial
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
NCT00484471 · Korea Otsuka International Asia Arab, Industry · Completed
Key facts
| NCT number | NCT00484471 |
|---|---|
| Title | ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness |
| Official title | A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder |
| Acronym | ABLE |
| Lead sponsor | Korea Otsuka International Asia Arab, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | aripiprazole, valproate, placebo |
| Enrollment | 127 |
| Start date | Oct 1, 2007 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2012 |
| First posted | Jun 11, 2007 |
| Last update posted | Mar 31, 2022 |
| Countries | Hong Kong, Philippines, Taiwan, Thailand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: